Abstract: The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.

Abstract: The present invention provides in one aspect azabicyclo and diazepine derivatives useful as modulators of muscarinic receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, the compositions comprising at least one muscarinic receptor modulator.

Abstract: According to one or more embodiments, a pottery wheel with an improved throwing arm for producing sculpted pottery, and more specifically, to an apparatus and method for producing customizable sculptured pottery using a pottery wheel having a throwing arm with appendage that articulates in multiple dimensions.

Abstract: Polymeric eye inserts are provided that may be dissolvable when placed in the cul-de-sac of the eye. These inserts may contain one or more polymers as well as a softener/plasticizer so that, when inserted into the eye, they may absorb tears, and dissolve and slowly release lubricant into the tear film to lubricate and protect the ocular surface for an extended duration of time. Increased retention time on the ocular surface for longer lasting relief may reduce dosing frequency and patient burden typically associated with topical drop usage. These polymeric eye inserts also may include one or more pharmaceutically active agents.

Abstract: The present disclosure is directed to pharmaceutical compositions comprising apraclonidine and a polymer, wherein the apraclonidine is present at greater than 0.05% (w/v) to no more than 0.2% (w/v) based on the total volume of the pharmaceutical composition, methods of preparing the same and methods for reducing ocular redness by administering the same.

Abstract: The present disclosure is directed to prodrugs, compositions including prodrugs, and methods for administering prodrugs and compositions thereof to a patient, including prodrugs represented by Formula (I): wherein: D is a drug moiety; Q is an oxygen atom, a sulfur atom, or a nitrogen atom; X is a chemical bond or each of G, G?, and G? is independently an oxygen atom or a sulfur atom; L is a polyether; T is a hydrogen atom, a hydroxyl group, a thiol group, a boronic acid group, or an amine group; R1 is selected from the group consisting of a substituted aryl group, unsubstituted aryl group, and a substituted carbonyl group; and each of R2, R3, R1?, R2?, R3?, and R4? is independently a hydrogen atom, a substituted C1-C20 alkyl group, or an unsubstituted C1 -C20 alkyl group. In at least one embodiment, a composition comprises a compound and a carrier material.

Abstract: The present invention provides in one aspect azabicyclo and diazepine derivatives useful as modulators of muscarinic receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, the compositions comprising at least one muscarinic receptor modulator.

Abstract: The present disclosure is directed, in part, to aqueous pharmaceutical solutions comprising benzyl atropine or a pharmaceutically acceptable salt or prodrug thereof, at least one buffer, at least one tonicity agent, and at least one solubilizing agent, processes of preparing an aqueous solution comprising benzyl atropine, the products of such processes, and methods of preventing myopia, treating myopia, reducing myopia progression, or preventing myopia progression in a subject in need thereof, by administering to the eye of the subject a therapeutically effective amount of such an aqueous pharmaceutical solution.

Abstract: The present invention provides in one aspect azabicyclo and diazepine derivatives useful as modulators of muscarinic receptors. In another aspect, the present invention provides pharmaceutical compositions for treating ocular diseases, the compositions comprising at least one muscarinic receptor modulator.

Abstract: Polymeric eye inserts are provided that may be dissolvable when placed in the cul-de-sac of the eye. These inserts may contain one or more polymers as well as a softener/plasticizer so that, when inserted into the eye, they may absorb tears, and dissolve and slowly release lubricant into the tear film to lubricate and protect the ocular surface for an extended duration of time. Increased retention time on the ocular surface for longer lasting relief may reduce dosing frequency and patient burden typically associated with topical drop usage. These polymeric eye inserts also may include one or more pharmaceutically active agents.

Abstract: Polymeric eye inserts are provided that may be dissolvable when placed in the cul-de-sac of the eye. These inserts may contain one or more mucoadhesive polymers, a biodegradable polymer as well as softener/plasticizer so that, when inserted into the eye, they may absorb tears, and dissolve and slowly release lubricant into the tear film to lubricate and protect the ocular surface for an extended duration of time. The biodegradable polymer containing eye insert may increase dissolution time on the ocular surface for longer lasting relief, may reduce dosing frequency and patient burden typically associated with topical drop usage. These polymeric eye inserts also may include one or more pharmaceutically active agents.

Abstract: The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery, In one embodiment of the present invention; the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound.

Abstract: The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.